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Studies have shown that pharmaceuticals and other personal care products (PPCPs) are 
present in the environment, especially in water, due to different human activities. Some 
of these compounds are toxic to our eco-system. Although there is no evidence of adverse 
human health effect from the presence of PPCPs in the environment  to date , some 
adverse effects on aquatic life cycle already have been found. Therefore, protecting our 
environment as well as human health from adverse effect(s) of PPCPs is a growing 
concern.      
 
The objective of this thesis work was to collect information about the principal 
approaches available to pharmaceutical industries for reducing the introduction of PPCPs 
to the environment and to identify and address any divergence or disagreement about the 
effectiveness of these approaches to address this issue. Through the use of literature 
review, case studies, and in-depth interviews where necessary, consistent information has 
been consolidated and discrepancies have been resolved to the extent possible and this 
reference document has been created for the purpose of fostering the awareness about this 
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Presence of pharmaceuticals and other personal care products in the environment is one 
of the most serious concerns today. There are different classes of chemicals recognized as 
continuing or emerging sources of contaminant that are continuously released to 
environment, mainly through different human activities. These classes include a wide 
variety of compounds  used in industry and in home, for example, surfactants, 
disinfectants, solvents, etc. and those that constitute prescription and nonprescription 
drugs like antibiotics, antacids, antimicrobials, etc. Besides these, sex and steroidal 
hormones are also being recognized as emerging contaminants of environment. All these 
compounds have high usage rates and also have potential health effects and  some 
undesirable effects on non-target organisms, including endocrine disruption and 
development of antibiotic resistance or toxicity (Lee, Zaugg, Cahill, and Furlong, 2000, 
58). 
 
The common sources of PPCPs in the environment are pharmaceutical 
wastewater, human excreta and disposal of unused prescription and non-prescription 
drugs. It is believed that concentrations of different chemicals in wastewater from 
pharmaceutical industries are negligible, in respect of producing any adverse effect on 
living creatures. But, still the concentrations of some of these chemicals are of a great 
concern as many of these chemical compounds have cumulative properties and after a 
couple of years, when these chemical compounds reach their MEC1 (Minimum Effective 
                                                 
1 MEC is the minimum amount of any chemical compound, in body’s circulatory system, required to 
produce any effect of that chemical within the body.  
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Concentration) in the environment, they produce adverse effects to living creatures to 
some extents.  
 
Proper disposal of unused prescription2 and non-prescription drugs is also 
important because most of the pharmaceuticals and personal care products get 
accumulated after disposal in the environment due to their resistant nature to biological 
degradation process and sometimes their adverse effects on non-target receptors3 can not 
be identified, even unpredictable, due to their low concentration applications. As for 
example, reproductive hormones like estrogen which is used for birth control in human 
also interfere with reproduction and development stages in reptiles. This estrogen 
hormone also results in widespread sexual disruption in male fishes. Similarly, some 
antidepressant pharmaceuticals like serotonin reuptake inhibitors inhibit growth rate in 
frogs and fishes. Sometimes, exposure to these accumulated PPCPs result in the 
development of drug resistant pathogenic organism4 in the environment. As for example, 
over use of antibiotics today, results in higher concentration of antibiotics residue in 
wastewater this in turn results in the creation of antibiotic resistant bacteria. Since, all 
these drug residues are present in very low concentration; it is difficult to identify their 
immediate adverse effect and combined effects of multiple PPCPs, the persistence and 
bioaccumulation of these compounds, and long term multi-generational effects5 are also 
difficult to predict. (Viadero. 2000,1) 
                                                 
2 Prescription is a physicians order for the preparation and administration of a drug or device for a patient. 
3 Receptor - a structure on the surface of a cell (or inside a cell) that selectively receives and binds a 
specific substance. 
4 Disease producing microorganism 
5 Information on the long-term health effects of low-level, long-term exposures of drug substances is 
particularly limited. 
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However, different approaches like product stewardship, end-of-pipe treatment 










Background (Preliminary) Literature Review: 
“Human exposure to environmental concentrations of pharmaceuticals6 is 
believed to be primarily through ingestion of drinking water and, for compounds 
that bio-accumulate, through ingestion of meat or fish” (Hagan 2000, 66).  
 
When pharmaceuticals and personal care products7 (PPCP) are present in very 
low concentrations in surface or groundwater, which is a source of drinking water, the 
most serious concern associated with their presence is not necessarily immediate acute 
effects on human health, but rather with the effects that can accumulate over a long 
                                                 
6 Pharmaceuticals are substances that are aimed to cure, prevent, or recognize diseases and relieve pains 
through their application in the organism. 
7 PPCP includes cosmetics, fragrances, skin care products, nutritional supplements, and over-the-counter 
medications. 
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period of time to produce truly distinguishable changes (Daughton & Ternes, 1999). 
Sometimes, it becomes difficult to identify any of these changes in certain non-target 
populations as they take a long period of time to occur. Current comprehensive 
environmental risk assessments and epidemiologic studies8 lack consideration of this 
type of long-term effects (Drewes, Heberer and Reddersen, 2002, 269). 
                                                
 
Sometimes, water characteristics get changed according to its use by humans. We 
use a variety of chemicals everyday for different purpose like for industrial purpose or for 
domestic purpose. After use, a portion of these chemicals find their way to either 
industrial wastewaters or domestic sewage. We are able to remove some of these 
chemicals through different treatment methods. After treatment, this wastewater is 
discharged to a receiving stream or water body. At any point of downstream flow of 
water, user receives the water and chemicals from all upstream users and this process 
goes to continue throughout the downstream of water flow. In this way, some chemicals 
are destroyed by means of some physical, chemical or biological treatment methods and 
those which remain unaffected, ultimately reaching a final receiver, e.g. oceans where 
they are precipitated due to evaporation of water and are accumulated (Hagan. 2000, 64). 
 
In some closed watersheds9, e.g., the Great Salt Lake, the final receptor is a lake 
and/or wetland. Planned reuse of treated wastewater is important in water-short 
 
8 Epidemiologic Studies - Studies designed to examine associations—commonly, hypothesized causal 
relations. They are usually concerned with identifying or measuring the effects of risk factors or exposures. 
The common types of epidemiologic studies are case-control studies, cohort studies, and cross-sectional 
studies. 
9 A watershed (also called a drainage basin or a catchment area) is defined as an area of land that intercepts 
and drains precipitation through a particular river system or group of river systems. In other words it is a 
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areas of the US and many other countries where water resources are limited 
relative to need. Planned reuse can be divided into two categories:  
(1) use that does not involve human consumption of the water such as 
irrigation of golf courses and landscaping; and  
(2) uses that result in human exposure, including drinking water supply.  
Planned reuse is currently always indirect rather than direct (i.e., using treated 
sewage effluent as drinking water supply influent). Indirect reuse includes 
recharging an aquifer used for a ground water supply with treated effluent and 
discharging treated effluent to a water supply reservoir (Hagan 2000, 64).  
Advanced sewage treatment methods like activated carbon adsorption and membrane 
filtration in conjunction with planned water reuse is always much more rigorous than that 
used for discharges to surface waters (Hagan 2000, 64).  
 
The contaminants enter the environment by means of different transport pathways 
such as, on one hand, through direct disposal in sewage systems and landfills, and on the 
other hand, as runoff or infiltration from fields following application of wastewater 
treatment sludge or animal manure (Lee, Zaugg, Cahill, and Furlong, 2000, 58). The 
main route by which pharmaceuticals enter the environment is via water discharges, as 
most of the pharmaceuticals found in the environment have been proved water-soluble. 
                                                                                                                                                 
region of interconnected rivers and streams which functions as a unified system for water transport. 
Watersheds may be of various forms: a closed watershed empties into an inland body of water, whereas an 
open watershed drains to the ocean. 
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Among the different routes into the environment, the therapeutic use10 of 
pharmaceuticals and the subsequent excretion of the active ingredients or their 
metabolites in urine and feces, quantitatively constitutes the most important one.  
                                                
 
When applying pharmaceuticals to humans, many of these compounds are 
excreted with only slight transformations or even unchanged and often conjugated 
to polar molecules (e.g. as glucoronides). Due to an incomplete elimination of a 
number of pharmaceuticals used in human medical care in sewage treatment 
plants several classes of drugs are found in sewage effluent. Among these classes 
are antirheumatics (e.g. Diclofenac), analgesics (e.g. Propyphenazone) as well as 
the above mentioned blood lipid regulators (e.g. Clofibric acid). High 
concentrations of sewage contaminants may be expected in the receiving surface 
waters with regard to the high contribution of sewage treatment work’s effluents, 
especially in areas with a high population density (Scheytt, Leidig, Marsmann and 
Heberer 2000, 253). The chemicals which are excreted by human beings, first 
enter into sewage treatment systems and then enter into surface water and 
groundwater when the treated wastes are discharged (Hagan. 2000, 64). 
 
Although it has been cited in some literature that neither manufacturing of 
pharmaceuticals nor disposal of sewage sludge on land constitute a major source of 
pharmaceuticals in the environment, still manufacturing, wastewater and waste from 
 
10 Therapeutic use means use for the purpose of preventing, diagnosing, curing or alleviating a disease, 
ailment, defect or injury in persons; or influencing, inhibiting or modifying a physiological process in 
persons; or testing the susceptibility of persons to a disease or ailment.  
  
 12
pharmaceutical industries are considered to be important sources. The pathways of 
contamination from disposal of sewage sludge would be to surface water by runoff that 
contacted the sludge or to ground water by precipitation that percolates through the 
sludge into an underlying aquifer (Hagan 2000, 64). Sewage Treatment plant effluent has 
been recognized a source of certain natural chemicals like human estrogen, caffeine etc., 
in the aquatic environment.  
 
In order to determine the right approach to address this issue, it is first necessary 
to identify what types of pharmaceuticals are normally found in the environment. But, 
unfortunately, still there is no single analytical method to detect all pharmaceuticals.  
Very sophisticated analytical research methods with very low detection limits and highest 
accuracy are necessary to detect most of the pharmaceuticals in the environment at very 
low concentrations.  Such testing can only be done by using special analytical equipment 
which is only available in certain analytical research laboratories, or certain commercial 
laboratories that also specialize in methods research (Pontius. 2002, 9).  
  
Information about the treatment methods of pharmaceutical compounds is not 
very common in the public literature. However, granular activated carbon, powdered 
activated carbon, nano-filtration and reverse osmosis are the most common methods used 
to remove synthetic organic pharmaceuticals compounds from water. Flocculation11 with 
ferric chloride and slow-sand filtration had proven ineffective as treatment processes to 
remove low levels of pharmaceuticals found in drinking-water where a combination of 
                                                 
11 Flocculation - The agglomeration of finely divided suspended solids into larger, usually gelatinous, 
particles. 
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ozonation and filtration with or without granular activated charcoal has been proven as a 
very important treatment (Pontius, 2002, 8).   
 
Again, in order to eliminate pharmaceuticals completely from wastewater and 
sewage sludge, it is assumed that an advanced treatment technology, like reverse 
osmosis, may be very effective.  Research is going on to determine the most effective 
wastewater treatment method.   
 
USEPA has not set a national primary drinking water regulation 
(NPDWR) for PPCPs.  USEPA believes there is not sufficient information to 
warrant regulation of PPCPs at this time.  (USEPA 2002b)  Other countries are 
considering how pharmaceuticals might be regulated.  (Lange and Dietrich 2002)   
Under the National Environmental Policy Act of 1969, the U.S. Food and 
Drug Administration (FDA) requires Environmental Assessments on the impact 
of individual pharmaceuticals on the environment.   (Daughton and Ternes 1999) 
USEPA does not require routine monitoring for PPCPs at this time.  USEPA has 
not included contaminants on the Drinking Water Contaminant Candidate List 
(DWCCL) solely on the possibility of their endocrine disruption potential. But, 
USEPA may add certain representative PPCPs to the DWCCL and Unregulated 
Contaminants Monitoring Rule (UCMR) in the future.  (USEPA 2002b) (Pontius. 
2002, 8)  
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Although, there is no drinking water regulation or routine monitoring requirement 
for PPCPs has been set by USEPA till-to-date because of the unavailability of enough 
information needed to justify regulating PPCPs in drinking water but, now-a-days federal 
regulators and scientists are becoming more and more concerned about the issues of 
emerging contaminants i.e. PPCPs and continue to include and evaluate PPCPs in 
contaminant selection process and carrying out research efforts to determine whether 
regulation is necessary or not (Grumbles. 2006). USEPA might reconsider drinking water 
regulations for all of these contaminants in near future. 
 
Today, many companies are using a cradle-to-cradle stewardship12 concept to 
address this issue. According to this concept, companies are taking many actions like 
altered drug design and packaging system for drugs, modified drug delivery pattern, 
improved drug dispensing methods, more effective methods of drug disposal, etc. in 
order to reduce the risk from introduction of pharmaceuticals into the environment. 
Manufacturing facilities are making every effort to assure that product is not lost to the 
waste stream. Manufacturing releases would be localized and likely a minor contributor 
to the environment. Some of these ideas for minimizing the release of PPCPs to the 
environment have already been put forth (Daughton and Ternes 1999). As per Daughton,  
“For true cradle-to-cradle stewardship of PPCPs, a holistic integration of all 
aspects of the production-consumption cycle is required – one that takes into 
consideration the needs and costs of the complete cycle from drug 
discovery/design to distribution, end use, and disposal/recycling.”  
  
                                                 
12 Cradle-to-cradle stewardship means extended product responsibilities. 
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In one study regarding the avenues towards “Green Pharmacy” by Christian G. 
Daughton, he recommended some methods for disposal of PPCPs by the end user i.e. 
disposal of drugs to domestic sewage systems is probably the least desirable way to 
dispose of any drug while the two better alternatives might include pharmacy take back 
program as a part of cradle-to-cradle stewardship and disposal in household trash 











I.Literature Review:  
For the purpose of this thesis work, a literature review has been conducted to collect 
information from the U.S. and Western Europe. That means literature published in these 
geographical areas have been reviewed as it is believed by the researcher that most 
advanced technologies are being practiced in the U.S. and Western Europe. 
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Literature published in English, from 1985 through the present have only been considered 
for review as it is assumed by the researcher that the technologies used before 1985, are 
mostly outdated now, particularly in these geographical area and bear no relevance with 
purpose of this thesis work. 
 
Articles from professional journals, books by acknowledged experts, papers published on 
the WebPages of academic institutions and professional organizations and official 
documents posted on WebPages of governmental agencies and corporations have been 
considered as an appropriate sources for review while writings from, supported by, or 
posted on the WebPages of: advertising or marketing groups, advocacy organizations, or 
organizations with vested interests in one outcome or another have been considered 
inappropriate sources of information for this thesis work. 
 
The literature review has been conducted thus to find out information to answer the 
following questions:  
• What are the approaches available to address the issue of PPCPs? 
• How effective are these approaches are to address this issue?  
• What are their limitations?  
• Is there any disagreement or discrepancy about the effectiveness of these 
approaches to address this issue? 
• Which one is the best approach (most effective) from all aspects? 
• Is there any possibility of improving the effectiveness of these approaches? 
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• What new approaches, companies are planning to take in future to address the 
issue of PPCPs? 
 
For the purpose of this thesis work, only manufacturing process stage in 
pharmaceutical industries has been considered as the potential source of contaminant to 
pharmaceutical wastewater and other stages of pharmaceuticals and other personal care 
products manufacturing like packaging etc. have been excluded from the list of potential 
sources of contaminant to wastewater. 
 
II. Case Studies  
Information has been collected, through case studies, about the view of pharmaceutical 
industries regarding the issue of pharmaceuticals and other personal care products in 
environment. Case study approach has been considered as an appropriate methodology 
for this work to answer ‘What’, ‘Why’, ‘How’ – types of questions, over which little or 
no control could be exerted, as there was no scope of any hand-on laboratory work during 
the course of this thesis work.  
 
For the purpose of case study, Websites of 10 leading pharmaceutical companies 
have been visited to find out specific information about their current approaches towards 
this issue and their future plan (if any) towards this issue. These 10 pharmaceutical 
companies have been selected for case study purpose based upon the availability of 
information, in their respective websites, required for this thesis work. Case studies have 
been performed by reviewing their electronic copies of annual report (s), EHS 
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performances, corporate responsibilities, and newsroom as it is believed that companies, 
in general, put their most recent environmental health and safety information in all or any 
one of these mentioned areas. Specifically, the following information has been looked for 
during case studies:  
• What current approaches are being taking? 
• How these approaches are being applied? 
• Why any company has chosen any particular approach?  
• What will be their next plan to address this issue? 
 
III. In-Depth Interviews  
For the purpose of this paper, in-depth interview processes with pharmaceutical company 
personnel have been conducted to verify the reliability of the information collected 
through literature survey and case study and to collect additional information about their 
specific approaches. Both EHS personnel as well as production personnel of 
pharmaceutical companies have been interviewed as it has been believed that these 
personnel keep the most updated EHS information of the respective companies and about 
their future EHS goal (s). Specifically, the following information has been looked for 
during this interview stage: 
• What are the most recent approaches from company’s perspective to address this 
issue? 
• Why they have chosen these particular approaches? 
• Why they are not using any other approaches? 
• What they are thinking to do in near future regarding this issue? 
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•  Are they doing so actually to protect our environment, or just due to some 
regulatory concern to look the company doing better? 
 
IV.Analysis  
Information about the past and present approaches of pharmaceutical companies towards 
the issues of PPCPs that collected through literature review, have been verified with that 
collected through case studies and finally, validated against the information collected 











I. Literature Review 
Generally, five types of manufacturing processes are common in pharmaceutical 
industries. These are research, fermentation13, biological or natural extraction14, chemical 
                                                 
13 Fermentation - The process of growing microorganisms to produce chemicals or pharmaceutical 
compounds. Microorganisms are usually grown under controlled condition in large tanks called fermentors. 
14 Extraction - the process of obtaining something from a mixture or compound by chemical or physical or 
mechanical means. 
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synthesis and finally, mixing-compounding-formulating. Many pharmaceutical industries 
use any one of these five manufacturing processes while the others use a combination of 
two or more manufacturing processes in their regular practice.  (The research type of 
manufacturing process has not been considered as a potential source of contaminant to 
wastewater for this thesis work as the volume of wastewater that produces everyday from 
a research process is negligible as compared to that of the other four types of 
manufacturing processes and therefore, has not been discussed further in this paper.)  
 
Examples of different classes of pharmaceutical products, manufactured by using 
the above four processes, are given in the following table: 
 
Table 1 
Type of Process Example of Pharmaceutical Products 
Fermentation Antibiotics – Chlortetracycline, Penicillin G, Penicillin V, 
Streptomycin;  Therapeutic Nutrients; Vitamins - Ascorbic 
acid (C), Riboflavin (B2); Steroids etc. 
Biological or natural 
extraction 
Enzymes and Digestive Aids; Central Depressants – 
Codeine, Morphine Sulfate; Hematological Agents – 
Heparin; Insulin etc.  
Chemical Synthesis Antibiotics – Clindamycin; Cardiovascular Agents – 
Methyldopa; Central Stimulants – Amitriptyline, Caffeine; 
Central Depressants – Acetaminophen, Aspirin; Hormones - 
Cortisone acetate, Dexamethasone acetate, Hydrocortisone, 
Testosterone; Vitamins – Niacinamide etc.  
Mixing, compounding or 
formulating 
Mouthwash – Listerine; Powders; Tablets and Capsules; 
Ointments – Caladryl, Vicks Vaporrub etc.  
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From a portfolio survey by EPA, it can be said that the number of pharmaceutical 
industry using the fermentation method is increasing since 1990 (USEPA Technical 
Development Document. 1998, 3-40). As per the survey report, this number has been 
increased by 100% since before 1990, while the use biological or natural extraction 
method has decreased by 15% and the other two methods have remained point as before. 
These manufacturing processes are being used in pharmaceutical industries, either in 
batch operation or in continuous operation or in a combination of both. Therefore, 
wastewater characteristics from different manufacturing facilities are not unique and vary 
according to the manufacturing process type.    
 
Fermentation process is very important in antibiotics and steroid manufacturing 
units. Fermentation is carried out as a large-scale batch operation. Therefore, before 
charging a new batch, water wash and sterilization of the fermenter vessel is a 
compulsory step to prevent cross contamination and phase infection. This wastewater 
from the fermenter vessel, spill cleanup water, wastewater that is generated from product 
recovery stage and that from liquid scrubber (often is used to clean fermentation waste-
off gas before discharging it to air), along with spent broth and infested batch (if any), 
constitute the waste stream of a fermentation unit.   
 
Biological or natural extraction is one of the most important process in 
pharmaceutical manufacturing because by this method, most of the natural active 
ingredients of medicinal and other personal care products are extracted from natural 
resources like plant, fungus etc. These active ingredients fall into different categories like 
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alkaloids, glycosides, tannins, resins, volatile oils etc. Different portion of plants are 
being used for these extraction processes, e.g., Senna leaves are used to extract sennoside 
alkaloid which is used as an active ingredient in laxative and purgative preparations; 
similarly, digitalis leaves are used to extracts dioxin and digitoxin glycosides which are 
active ingredients in many cardiac medicinal preparations like those are used in cardiac 
arrhythmia15 etc; similarly, clove oil is used as dental analgesic, antiseptic preparation 
etc. . Many of the natural volatile oils, extracted by this method, are used as flavoring 
agents in different cosmetics preparations like, soaps, body spray, cream etc. Therefore, 
biological or natural extraction processes are very much essential in pharmaceutical and 
other personal care products manufacturing.  
 
In this extractive process, the active ingredient(s) is (are) extracted with a solvent 
or with a mixture of solvents, depending on the specific type of active ingredient(s) 
through a series of batch operations. This equipment wash water, spent raw material like 
plant residue, chemical waste like spent solvent, spill cleanup water etc. are considered  
the major sources of waste in the effluent of a extraction unit. The waste load in the 
effluent is normally very high because natural active ingredients are present in a very 
minute quantity in the plant or animal sources. Solid wastes constitute the major portion 
of this waste load.   
 
Chemical synthesis is another important method of pharmaceutical manufacturing 
and is now being widely used in the industry to manufacture medicinal and other 
                                                 
15 Cardiac Arrhythmia - Irregularity of the heartbeat caused by damage to or defects in the heart tissue and 
its electrical system. An unusually fast rhythm (more than 100 beats per minute) is called tachycardia. An 
unusually slow rhythm (fewer than 60 beats per minute) is called bradycardia. 
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cosmetic products where the biological method is not economically feasible and the 
required ingredients can be manufactured in a chemical set up, using a number of organic 
and/or inorganic chemical reactions. This is a batch operating process.  
 
In chemical synthesis, the same equipment is used for different product 
manufacturing and the wastes characteristics vary accordingly. The equipment wash 
water, process waste like spent solvents, precipitates, reaction by-products etc., spill 
cleanup water, wet scrubber water etc. are the major sources of contaminant of the 
wastewater effluent from a chemical synthesis unit.  
 
Active ingredients are converted into different dosage form like tablet, capsule, 
liquid preparations etc. by the mixing, compounding or formulating processes. These 
dosage forms are the final usable forms. The equipment wash water, floor wash water, 
water from wet scrubber and spill cleanup water are the major sources of wastewater in a 
mixing, compounding or formulating unit.  
 
Therefore, all types of pharmaceutical manufacturing industry generate 
wastewater containing a variety of pollutants. Generally, three types of pollutants are 
presents in pharmaceutical wastewater. These are conventional pollutants, priority 
pollutants and non-conventional pollutants. The following table represents a general list 












Acetaldehyde, Acetic acid, Acetone, Acetonitrile, Acetophenone, Allyl 
chloride, 4-Aminobiphenyl, Ammonia, n-Amyl acetate 
Amyl alcohol, Aniline, Benzaldehyde, Benzotrichloride, Benzyl 
alcohol, Benzyl chloride, Benzyl bromide, Biphenyl, 
Bis(chloromethyl)ether, 2-Bromo-Propanoylbromide, 2-Butanone 
(MEK), n-Butyl acetate, n-Butyl alcohol, tert-Butyl alcohol, sec-Butyl 
alcohol, n-Butylamine, Carbon disulfide, Catechol, Chloroacetic acid 
2-Chloroacetophenone, 3-Chloro-4-Fluoroaniline, Chloromethyl 
methyl ether, COD, Cresol (Mixed), Cumene, Cyclohexane, 
Cyclohexanone, Cyclopentanone, Cyclohexylamine,  
1,2-Dibromoethane, 1,2-trans-Dichloroethene, Diethylaniline,  
Diethyl ether, Diethylamine, Diethyl carbonate, Diethyl-ortho formate  
Dimethylamine, 1,1-Dimethylhydrazine, N,N-Dimethylacetamide  
N,N-Dimethylformamide, N,N-Dimethylaniline, Dimethylcarbamyl 
chloride, Dimethyl sulfoxide, 1,4-Dioxane, N-Dipropylamine, 
Epichlorohydrin, Ethanol, Ethylene oxide, Ethylamine, Ethyl bromide  
Ethyl cellosolve, Ethyl acetate, Ethylene glycol, Ethyl cyanide, 
Formaldehyde, Formamide, Formic acid, Furfural, Glycol ethers, n-
Heptane, 2-Hexanone, n-Hexane, Hydrazine, Iodoethane, 
Iodomethane, Isobutyraldehyde, Isopropyl ether, Isopropanol, 
Isopropyl acetate, Isobutyl alcohol, Methanol, Methyl cellosolve 
Methyl amine, Methyl formate, 2-Methyl pyridine, 2-Methoxyaniline, 
Methyl methacrylate, Methyl-t-butyl-ether, Methylal, Methyl isobutyl 
ketone (MIBK), N-Nitrosomorpholine, n-Octane, n-Pentane, 
Petroleum naphtha, Polethylene glycol 600, 1,3-Propane sulfone 
n-Propanol, B-Propiolactone, Propionaldehyde, 1,2-Propyleneimine 
Propylene oxide, Pyridine, Styrene, Tetrachloroethene, 
Tetrahydrofuran, Trichlorofluoromethane, 2,4,5-Trichlorophenol, 
Triethylamine, Vinyl acetate, Xylenes 
Priority 
Pollutants 
Acrolein, Acrylonitrile, Benzene, Benzidine, Bromoform, 
Bromomethane, Chlorobenzene, Chloroethane, Chloroform, 
Chloromethane, Cyanide, 1,1-Dichloroethane, 1,2-Dichloroethane  
1,1-Dichloroethene, 1,2-Dichloropropane, Ethylbenzene, 
Hexachlorocyclopentadiene, Hexachloroethane, Methylene chloride  
Nitrobenzene, 2-Nitrophenol, 4-Nitrophenol, o-Dichlorobenzene  
p-Dichlorobenzene, Phenol, 1,1,2,2-Tetrachloroethane,  
Tetrachloromethane, Toluene, 1,1,1-Trichloroethane, 
Trichloroethylene, 1,1,2-Trichloroethane, Vinyl chloride. 
(Source: USEPA Technical Development Document. 1998, Table 6-1, 6-12) 
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Wastewater is characterized in terms of its BOD516, COD17, TSS content, flow 
rate and pH. These characteristics of wastewater from different pharmaceutical industries 
vary according to the specific type of manufacturing process. The following table 
represents a general comparison of the characteristics of wastewaters from four different 




of  Process BOD5 COD TSS Flow Rate pH 
Fermentation High High High Large 4.0 – 8.0 
Biological or Natural 
Extraction Low  Low Low Small 6.0 – 8.0 
Chemical Synthesis High  High High Large 1.0 – 11.0 
Mixing, Compounding 
or Formulating Low  Low Low Small 6.0 – 8.0 
  (Source: USEPA Technical Development Document. 1998, 3-29:38)  
But, in actual practice, each pharmaceutical industry uses a combination of two or more 
of the above four processes. Therefore, the characteristics of wastewater vary from 
industry to industry, depending on the types of processes in use.  
 
Pharmaceutical industries discharge these wastewaters to the water of United 
States either directly or indirectly through publicly owned treatment works (POTWs). It 
is generally believed that concentrations of different chemicals in wastewater from the 
pharmaceutical industries are negligible, with respect to the potential of producing any 
adverse effect on living creatures. However, recent studies have shown that although 
                                                 
16 BOD5 - Biochemical Oxygen Demand is a biological laboratory procedure that measures the rate of 
oxygen use while stabilizing decomposable organic mater under controlled conditions of time (5 days) and 
temperature (20ºC). 
17 COD (Chemical oxygen demand) - the amount of oxygen in mg/l required to oxidize both organic and 
oxidizable inorganic compounds. 
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these chemicals are present in a minute quantity, some of them produce adverse effects 
on aquatic life due to their cumulative effects. To address this issue, besides onsite 
wastewater treatment technologies, pharmaceutical industries are using product 
stewardship technology. The following table represents the common trends in treatment 




Percentage of facilities 
using this type of 
treatment technology 
Prior to 1990
Percentage of facilities 
using this type of 
treatment technology in 
1990 Onward 
Neutralization 26.0 44.3 
Equalization 20.1 28.6 
Activated sludge 16.9 20.5 
Settleable solids removal 13.3 NA 
Primary sedimentation 12.0 NA 
Aerated lagoon 7.5 4.9 
Primary clarification 3.9 9.8 
Chlorination 3.6 2.5 
Polishing ponds 3.2 NA 
Waste stabilization pond 2.9 2.5 
Trickling filter 2.9 2.0 
Multimedia filtration 2.3 6.1 
Steam stripping 1.9 5.7 
Evaporation 1.9 NA 
Secondary clarification 1.6 20.9 
Granular activated carbon 1.3 3.3 
Oxidation 1.0 2.0 
Dissolved air flotation 1.0 NA 
pH adjustment NA 50.0 
Phase separation NA 12.3 
      (Source: USEPA TDD. 1998, Table 3-9, 3-53) NA – Not Available from Survey data. 
The total of the percentage in both the columns is not equal to 100 because some 
industries use more than one treatment technologies while some industries do not operate 
any onsite treatment unit.   
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The major onsite wastewater treatment technologies (USEPA Technical Development 
Document. 1998, 7-1) are as follows: 
1. pH adjustment or neutralization 
2. Equalization 
3. Advanced biological treatment  
4. Cyanide destruction 
5. Multi-media or Multi-layer filtration 
6. Polishing pond treatment 
7. Steam stripping and steam stripping with rectification 
8. Granular activated carbon adsorption 
9. Air stripping  




1. pH Adjustment/Neutralization: 
Effectiveness of most of the pharmaceutical wastewater treatment technologies depend 
on the pH of the wastewater stream and these treatment technologies work best at a 
certain specific pH range. Therefore, pH adjustment or neutralization is usually done 
prior to many wastewater treatment operations. In any type of sedimentation process, pH 
adjustment or neutralization is important because solubility of most of the constituents in 
pharmaceutical wastewater is pH dependent. pH adjustment units usually consist of a 
mixing tank, stirring equipment and feed system for chemicals. pH is adjusted in the 
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mixing tank by adding either acids or alkali, depending on the desired pH.  The pH of 
final discharge is usually adjusted to between 6 and 8.5. (Guyer, H. 1998; 103) 
Advantage:  
• pH adjustment is used as a pretreatment technology, prior to many physical, 
chemical and biological wastewater treatment processes to improve their 
effectiveness.  
• pH adjustment is very much important for maintaining structural integrity of the 
membrane in filtration unit.  
• pH adjustment is also useful in reducing total solid content of wastewater stream 
through precipitation of many compounds whose solubility is pH dependent.   
Limitation:  
• This is a chemical addition process. Therefore, this process increases total 
chemical load of the wastewater.  





In any particular production day in a pharmaceutical industry, wastewater flow rate from 
different production units will vary according to the speed of the processes and thereby, 
sometimes overload and affect the performance of different wastewater treatment units. 
For example, biological and chemical treatment units work best at a constant inlet 
wastewater flow rate because it guarantees adequate process retention time. Similarly in 
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other wastewater treatment process like gravity sedimentation i.e. polishing pond 
treatment, fluctuation in the influent flow rate disturbs solid settling process and reduces 
treatment unit effectiveness. Therefore, equalization of wastewater flow rate through a 
wastewater treatment unit is very important for overall performance of the unit.  
 
The equalization of flow prevents surges i.e. short term, high volumes of 
incoming flow and controls the flow through each stage of the treatment system, allowing 
adequate time for the physical, biological and chemical processes to take place. 
Equalization unit consists of large tanks or basins where a certain percentage of daily 
wastewater streams is held to stabilize flow turbulence and is then discharged at a 
constant flow rate to downstream treatment units.  
Advantage:  
• Flow equalization eliminates or at least minimizes shock loadings throughout the 
downstream of wastewater treatment processes, thereby enhances performance of 
those treatment processes.  
• Flow equalization prevents system overloading. 
• Equalization tanks consolidate smaller volumes of wastewater streams so that, for 
batch treatment systems, full batch volumes are available. 
Limitations: 
• Flow equalization unit requires large land areas which increases capital cost. 





3. Advanced Biological Treatment: 
Advanced biological treatment is a very useful method of degrading various organic 
constituents in pharmaceutical wastewater and hence, is widely used in pharmaceutical 
manufacturing industries to treat BOD5, COD, and TSS of wastewater stream. In fact, by 
using this method, BOD5 and COD of wastewater stream can be reduced by 90% and 
75% respectively, in respect of their values in untreated wastewater.  (USEPA Technical 
Development Document. 1998, 7-11) 
 
Biological treatment of wastewater can be carried out either in presence of oxygen which 
is also called aerobic treatment or in absence of oxygen which is also called as anaerobic 
treatment. Again, under the aerobic biological treatment methods, different technologies 
are available like activated sludge process, surface impoundments, trickling filters, 
rotating biological contractors (RBC), sequencing batch reactors (SBR) and others, out of 
which, only first four methods are in common use in pharmaceutical manufacturing 
industries. Among these four methods, the basic mechanism of activated sludge process 
and surface impoundment process is the suspended growth technique in which 
microorganisms are kept suspended within the liquid being treated and thus, allowed to 
come into contact with the suspended and dissolved organic and nonmetallic inorganic 
wastes. The basic mechanism of trickling filter and rotating biological contactors is the 
fixed-film technique in which microorganisms are allowed to grow on a supporting 
medium and form a biological slime layer and as the wastewater passes through the unit, 
suspended and dissolved organic and nonmetallic wastes come in contact with the slime 
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layer and decompose into carbon dioxide, water, nitrate, sulfate, organic byproducts and 
cellular biomass. In both suspended growth and fixed film techniques, oxygen, nitrogen 
and phosphorous are supplied to maintain the microbial load in the units. (Guyer, H. 
1998; 151-6) 
 
The essential parts of an activated sludge treatment system are an equalization 
basin, a primary clarifier, an aeration basin, a secondary clarifier, and a sludge recycle 
line. Prior to aeration step, settleable solids are removed in a settling tank which acts as 
primary clarifier. Oxygen, recycled sludge, and nutrients are added to the aeration basin 
to maintain the microorganism population. Microorganisms are kept suspended in the 
aeration basin by the flow of oxygen, supplied by aerators. The secondary clarifier is 
necessary to control the amount of suspended solids to be discharged and the sludge is 
also obtained from this clarifier for recirculating to the aerated basin. For optimum 
performance of the activated sludge system, equalization of flow, pH, temperature, and 
pollutant loads is very important. (USEPA Technical Development Document.1998, 7-
12) 
Biological waste products and expired microorganisms are the primary 
constituents of the generated sludge which is further treated to reduce overall volume 
prior to disposal. The commonly used treatment methods are sludge thickening and 
sludge dewatering. Gravity separation, dissolved air flotation, or centrifugation technique 
is used for sludge thickening and filtration techniques like filter press, vacuum filter etc. 
is used for sludge dewatering. Nutrient-to-microorganism ratio, sludge production rate, 
percent BOD5 of effluent TSS, sludge retention time etc. are the some important 
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parameter of activated sludge treatment system. Advanced biological treatment method, 
when combined with nitrification, is also useful to reduce ammonia content of the 
wastewater. This can be achieved by incorporating two sets of autotrophic18 
microorganisms in biological treatment units. One set of microorganisms i.e. 
Nitrosomonas bacteria, converts ammonia to nitrites while the other one i.e. Nitrobacter 
bacteria, converts nitrites to nitrates. Nitrification capability can be determined through 
biological monitoring of both of the ammonia oxidizing bacteria and nitrite oxidizing 
bacteria. It also can be determined by analyzing the nitrogen balance between the amount 
of ammonia and that of the nitrite and nitrate (USEPA Technical Development 
Document. 1998, 7-13). 
Advantage: 
• Activated sludge process produce a very clean effluent within a reasonable period 
of time. 
• Activated sludge process is not usually affected by external temperature 
conditions. 
• Surface impoundment process is the cheapest method of organic waste treatment. 
• Potentially toxic chemicals can be treated biologically by surface impoundment 
process as the toxic chemicals get diluted due to large volume of the treatment 
unit. 
• Wastewater streams containing large variations of content can be effectively 
treated by Sequential batch reactor (SBR). 
                                                 
18 Autotrophic microorganism - An organism that makes its own food (as in plants) 
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• Rotating biological contractor (RBC) can tolerate large surges in wastewater 
concentrations.  
• Rotating biological contractor (RBC) requires low energy for operation. 
Limitations: 
• Activated sludge process requires high amount of energy for operation. 
• Surface impoundment process is less effective during winter season as the process 
is sensitive to temperature fluctuations. 
• Rotating biological contractor (RBC) requires high installation cost and high 








4. Cyanide Destruction 
Cyanide compounds are highly toxic, not only to human beings but also to aquatic life as 
they disturb their reproductive cycle and developmental stages. These compounds also 
have neurotoxic effect. Thereby, removal of cyanide compounds or cyanide ions from 
pharmaceutical wastewater is very important. Cyanide destruction methods are used for 
this purpose. Cyanide destruction is a chemical treatment method by which cyanide is 
converted to either inactive nitrogen gas or ammonia. Three chemical treatment methods 
are widely used in pharmaceutical industries for cyanide destruction. These are alkaline 
chlorination, hydrogen peroxide oxidation and basis hydrolysis method. All of these three 
methods are batch operating methods. The choice of treatment method depends upon the 
nature of cyanide compounds present in the wastewater stream.  
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The alkaline chlorine treatment unit usually consists of two reaction vessels and 
an equalization tank for storing of accumulated wastewater during treatment operation 
(USEPA Technical Development Document.1998, 7-18). This reaction is a two step 
process and is carried out separately in two reaction vessels. In the first step, sodium 
hypochlorite reacts with cyanide ions of the wastewater stream and oxidizes cyanide to 
cyanate ion (and also cyanogen chloride which is hydrolyzed to cyanate ion). In the 
second step, this cyanate ion further oxidized by hypochlorite ion to nitrogen gas and 
carbon dioxide. Temperature, pH and red-ox potential are important factors for the 
effectiveness of this treatment process. 
 
The hydrogen peroxide treatment unit usually consists of a reaction vessel, 
hydrogen peroxide storage vessel, equalization tank, and feed systems for chemicals 
(USEPA TDD.1998, 7-18). In the reaction vessel, hydrogen peroxide oxidizes the 
cyanide ion to produce cyanate and water. The cyanate then hydrolyses over time 
depending on the pH to give carbon dioxide and an ammonium salt or carbonate and 
ammonia. To accelerate the reaction speed, sometimes copper sulfate is used as a 
catalyst. Temperature and pH are important factors for the effectiveness of this treatment 
process.  
 
The basic hydrolysis treatment unit usually consists of a reaction vessel, storage 
vessel and feed system for chemicals and heat exchanger (USEPA TDD.1998, 7-18). In 
this process, cyanide ion reacts with water in presence of a base like sodium hydroxide 
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and produces formate and ammonia. Temperature and pH are important factors for the 
effectiveness of this treatment process. 
   
Advantages: 
• Alkaline chlorination process, in presence of heat, with an extended retention time 
results in complete destruction of total cyanides of wastewater stream.  
Limitations: 
• Alkaline chlorination process cannot effectively oxidize stable iron, copper, and 
nickel cyanide complexes. 
• Hydrogen peroxide method requires high pH. 
• Hydrogen peroxide method is slow and requires copper catalyst to accelerate the 
reaction rate. 







5. Multi-media or Multi-layer Filtration 
 
BOD5 content of wastewater is, in part, due its Total Suspended Solid (TSS) content and 
this part of the total BOD5 content can be reduced by reducing the amount of particulate 
matter of wastewater through filtration technologies. To reduce TSS in wastewater, 
particularly multi-layer or multi-media filtration technology is used in pharmaceutical 
industries. This method is also useful in dewatering of sludge. As the name implies, this 
filtration unit is composed of a series of different types of filtering media. These typically 
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consist of layers of activated charcoal, anthracite or hard coal, assorted rocks or gravels, 
garnet or fine sand. Theses layers are arranged in descending order of their granule size 
i.e. layer with the coarsest granular material is at the top of the filtering bed while the 
finest granular material is at the bottom of the bed to facilitate the flow of wastewater 
from inflow to outflow direction of the bed. The waste stream enters at the top of the 
filter bed and as the wastewater percolates through the upper porous layers, the larger 
suspended particles are trapped in and on to the upper porous layers of the bed. Smaller 
particles, not trapped, continue into the lower layers of the bed. As the particle size in the 
lower layers becomes smaller progressively, the space between the particles is reduced, 
thereby trapping increasingly smaller suspended particles and thus increasing the capacity 
of the filtration unit. As the wastewater passes through this filtering bed, suspended solids 
are removed from the wastewater by any or a combination of straining, impaction, 
sedimentation, interception and adsorption process. (Guyer, H. 1998; 72) 
 
Multimedia filtration is a batch process and the filtration is continued until the 
solids concentration increases to an unacceptable level in the effluent of the filtration 
unit. Under such a condition, cleaning of the bed is done by backwashing of the filtering 
media with a strong stream of clean water which is introduced at the bottom of the bed. 
This process agitates or fluidized the filtering bed materials where the trapped solid 
particulate matters get released from the bed and the concentrated wash water is pumped 
off and is either returned to the biological treatment system or sent for further processing. 
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Wastewater flow rate, hydraulic loading rate, and filter medium depth are the 
important factors to be considered for effective operation of the multimedia filtration unit 
(USEPA TDD. 1998, 7-15). 
Advantages: 
• Multi-media filtration systems are able to filter a wastewater stream with a very 
high amount of turbidity or suspended solids. 
• Multi-media filtration units filter wastewater streams at a much higher flow rate 
than a single-media filtration unit. 
• Multi-media filtration units have a longer running time than a single media 
filtration unit.  
• Multi-media filtration units require less backwash water per unit volume of 
filtrate as the bed can hold more turbidity than that of a single media filtration unit 
because suspended solids are trapped and held throughout the entire bed depth.  
• A very high degree of clarity is achieved because pore size of the filtration bed 
decreases as the wastewater stream passes towards bottom of the bed. (Guyer, H. 
1998; 73) 
Limitations: 
• Multi-media filtration process involves high labor cost.  
 
 
6. Polishing Pond Treatment 
Sedimentation technology is also used in pharmaceutical industry to reduce TSS content 
of wastewater stream. Polishing pond treatment process uses sedimentation technology 
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where a wastewater stream that enters at one end point of the pond is allowed to remain 
there for a pre-designated period of time, during which suspended solid (TSS) materials 
settle to the bottom of the pond due to gravitational force and the supernatant wastewater 
stream flows out the other end point of the pond (Guyer, H. 1998; 153-4). This process 
also reduces some TSS associated BOD5 content of the wastewater stream due to removal 
of TSS from the wastewater stream.  
 
This is a batch process. The water retention time and wastewater stream velocity 
are the important factors for the maximum effectiveness of this treatment technology 
because these two factors should be set as such to allow maximum settling of TSS out of 
the wastewater stream. The standard retention time is 14 to 15 days. The depth of the 
polishing pond should be small to avoid anaerobic condition. The polishing pond usually 
requires two liners and a leak detection system. (USEPA Technical Development 
Document. 1998, 7-17) 
Advantage: 
• Simple in operation. 
Limitations: 
• Application of polishing pond is limited to wastewater stream containing 
materials that are not restricted from land disposal.  
• Polishing pond treatment requires the use of large amount of land areas.  





7. Steam stripping and steam stripping with rectification 
Another important wastewater treatment technology in pharmaceutical manufacturing 
industries is steam stripping and/or steam stripping with rectification. This method works 
on the basic principle of relative volatility differences between organic chemicals and/or 
inorganic gases like ammonia, and water, thereby separates organic chemicals and/or 
ammonia from wastewater stream as it passes through the unit. This method is very 
useful in treating a variety of wastewater streams, containing a single to a complex 
mixture of the volatile constituents. The unit is installed immediately after the wastewater 
generating unit for maximum effectiveness of the treatment operation.  
Steam stripping and steam stripping with rectification can be conducted as 
either a batch or continuous operation in a packed tower or fractionating column 
(sieve tray or bubble cap) with more than one stage of vapor-liquid contact. In a 
steam stripping column, the wastewater feed enters near the top of the column and 
then flows downward by gravity, countercurrent to the steam which is introduced 
at the bottom of the column. In a steam stripping with rectification column, the 
wastewater feed enters lower down the column to allow for a rectification above 
the feed. In the rectification section, a portion of the condensed vapors are 
refluxed to the column to counter currently contact the rising vapors. This process 
concentrates the volatile components in the overhead stream. 
 
Steam may either be directly injected or re-boiled, although direct 
injection is more common. The steam strips volatile pollutants from the 
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wastewater, which are then included in the upward vapor flow. As a result, the 
wastewater contains progressively lower concentrations of volatile compounds as 
it moves toward the bottom of the column. The extent of separation is governed 
by physical properties of the volatile pollutants being stripped, the temperature 
and pressure at which the column is operated, and the arrangement and type of 
equipment used.  
 
The difference between steam stripping columns and steam stripping with 
rectification columns is the location of the feed stream. Stripping columns have a 
feed stream located near the top of the column while steams stripping with 
rectification columns have a feed stream located further down the column. 
Pollutants that phase separate from water can usually be stripped from the 
wastewater in a steam stripper (a column without rectifying stages). Pollutants 
that are not phase-separable, such as methanol, need a column with rectifying 
stages to achieve a high concentration of the pollutants in the overhead stream. 
 
The typical construction material for steam stripping and steam stripping 
with rectification columns in the pharmaceutical manufacturing industry is 
stainless steel. If a wastewater stream is highly corrosive, a more corrosion-
resistant material, such as Hastelloy or Teflon®-lined carbon steel, may be 
required for construction of the column. The majority of pharmaceutical 
manufacturing facilities which currently use steam stripping and/or steam 
stripping with rectification columns to treat their wastewater use stainless steel. 
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Salts and other pollutants may contribute to scaling and corrosion inside the 
column. Timely maintenance should be provided to deter scaling problems.  
Generally, columns with smaller diameters are packed while columns with larger 
diameters have trays. Typical column packings are Pall rings, Rashing rings, Berl 
saddles, and Intalox saddles. The key design parameters for stripping columns are 
the steam-to-feed ratio and the number of trays or equilibrium stages in packed 
columns. These parameters are calculated using the equilibrium ratio of the least 
strippable contaminant in the wastewater stream and the removal efficiency 
required to treat the contaminant to the desired concentration. Typical ranges for 
steam-to-feed ratios vary from 1:3 to 1:35, and the typical number of trays or 
equilibrium stages vary from 2 to 20 (USEPA Technical Development 
Document.1998, 7-19; 21). 
Advantages: 
• The main advantage of stream stripping is that, unlike air stripping, resultant off-
gas stream is usually condensed and the contained constituents is recovered or 
incinerated.  
• Steam stripping removes both volatile organic and volatile inorganic constituents 
of wastewater stream. 
Limitations:  
• Steam stripping is operated at higher temperatures and some times results in heat 
stress in the surrounding environment. 
• Steam stripping process involves high operational and maintenance cost. 
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8. Granular Activated Carbon Adsorption 
Adsorption is one of the surfaces phenomenon by which dissolved or suspended materials 
can be removed from a gas or a liquid stream through bond formation with the bonding 
sites of a solid adsorbent surface. Different types of adsorbents like, activated carbon, 
silica gel, alumina etc. are available for this purpose but, granular activated carbon is 
considered the best among all of these adsorbents due to its hydrophobic nature, high 
internal surface area and high surface bonding affinity to most of the other compounds. 
Therefore, granular activated carbon adsorption method is widely used to reduce BOD5, 
COD and organic constituents of pharmaceutical wastewater. 
 
Activated carbon is prepared by destructive distillation of carbon containing 
materials like coconut shell, wood etc and then either it is powdered or broken down to 
granule size to increase its internal surface area.  
 
In wastewater treatment unit, either activated carbon is packed into columns or 
bed of activated carbon is prepared into large enclosed tanks. Enclosed tanks are more 
common in wastewater treatment and more than one tank is use in series to ensure 
maximum effectiveness of the treatment process. When wastewater passes through these 
columns or tanks, its constituents come in contact with the surface of activated carbon 
and get adsorbed on to the surface of the activated carbon due to bond formation with the 
surface bonding sites. As the time goes on, the surface area of the upper layer of activated 
carbon bed becomes saturated and consequently, the adsorption zone moves downward to 
the lower level. This process continues until almost all of the activated carbon in the bed 
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becomes saturated and the constituents of wastewater, being treated, appear in the 
effluent of treatment unit at a higher value than the acceptable limit. At this point, the 
activated carbon is called spent. This spent activated carbon can be regenerated by 
destructive distillation or by backwashing with steam or by chemical treatment. After a 
few cycle of regeneration, adsorbing capacity of the activated carbon goes down below 
the acceptable level and then it is disposed off. (Guyer, H. 1998; 88-89) 
  
The effectiveness of wastewater treatment by granular activated carbon 
adsorption process depends on three important factors. These are wastewater TSS 
concentration, saturation loading and hydraulic loading. (USEPA Technical Development 
Document.1998, 7-24) 
Advantages: 
• Low space is required for GAC. 
• One major advantage of Granular Activated Carbon technology is its ability to 
remove a wide variety of toxic organic compounds to non-detectable level 
(99.99%)  




• GAC unit works best at low suspended solids concentration of wastewater.  
• Bacterial growth in granular carbon beds generates hydrogen sulfide which 
creates odors and corrosion problems.  
• GAC adsorption is highly sensitive to pH, temperature, and flow rate of 
wastewater. 
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• Wet spent carbon from GAC unit is highly corrosive and abrasive creates land 




9.  Air Stripping 
Air stripping technology is very useful in removing volatile organic compounds (VOCs) 
as well as volatile inorganic compounds like ammonia, from pharmaceutical wastewater 
stream. Air stripping is carried out either in a countercurrent, packed column or in an 
aeration tank. In these treatment units, wastewater is sprayed by a spray nozzle at the top 
of the unit. As the wastewater descends through the treatment unit, air is forced upward 
through the unit, stripping off the volatile compounds and then the volatile compounds 
are carried out of the system at the top of the unit with air stream. Internal baffles inside 
the treatment unit increase surface area of the wastewater and thereby, increase 
wastewater-air contact and thus maximize volatilization of volatile compounds from 
wastewater. Effluent of these treatment units is discharged at the bottom of the units. 
(USEPA Technical Development Document. 1998, 7-28)  
Advantages: 
• Air stripping removes both volatile organic and volatile inorganic constituents of 
wastewater stream. 





• It removes volatile contaminants from wastewater stream but, discharges the same 
contaminants into the surrounding atmosphere. 
• At low temperature, air stripping is less efficient and there is a possibility of 





10.  Incineration 
Incineration is used in pharmaceutical industries where diverse toxic or very toxic 
wastewater streams are produced due to chemical multi-products production operations 
and these wastewater streams cannot be routed to a conventional wastewater treatment 
plant. Different types of incinerators are available for this purpose like rotary-kiln, 
fluidized bed, multiple/stepped hearth etc. Among this, fluidized bed and multiple hearth 
incinerators are more common in pharmaceutical industries. An acid gas scrubber is used 
to control Hydrochloric acid that is generated during incineration. In this process, organic 
and inorganic contaminants of wastewater are thermally destroyed to ash and the 
resultant water vapor is discharged to air. (USEPA Technical Development 
Document.1998, 7-29) 
Advantage: 
• Incineration is the most effective way of complete destruction of all contaminants 
of wastewater stream. 
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• Complete incineration destroys chemical properties of hazardous wastes. 
Limitations: 




Product stewardship is a broad term and is a product-centered concept of reducing 
environmental impacts of a product throughout its life cycle, through shared 
responsibility of manufacturer, retailers, users and disposers. As per EPA –  
In most cases, manufacturers have the greatest ability, and therefore the greatest 
responsibility, to reduce the environmental impacts of their products. Companies 
that are accepting the challenge are recognizing that product stewardship also 
represents a substantial business opportunity. By rethinking their products, their 
relationships with the supply chain, and the ultimate customer, some 
manufacturers are dramatically increasing their productivity, reducing costs, 
fostering product and market innovation, and providing customers with more 
value at less environmental impact. Reducing use of toxic substances, designing 
for reuse and recyclability, and creating take-back programs are just a few of the 
many opportunities for companies to become better environmental stewards of 
their products. (EPA Product Stewardship, July 2007) 
 
To address the issues of pharmaceuticals and other personal care products in the 
environment, pharmaceutical manufacturers should have to take on new responsibility for 
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reducing the environmental impacts of their products. Currently, pharmaceutical 
manufacturers are exercising different product stewardship programs like formulation 
alteration or modification, pharmaceuticals mail-back program, pharmacy take-back 
program etc. In fact, all of these product stewardship programs are proactive approaches 
to address the PPCPs issues. All these approaches are very important as majority of this 
PPCPs issue is due to fecal excretion of non-metabolized or incomplete metabolized 
portion of drug formulations, improper method of disposal of unused prescription and 
non-prescription drugs or personal care products present in household wastewater.  
 
Formulation alteration or modification 
When a drug is administered through any of the local routes (like gastrointestinal tract, 
vagina, bronchi, eye, ear etc.) or systemic routes (like parenteral, rectal, sublingual etc),   
it undergoes four basic processes within the body. These are absorption, distribution, 
metabolism and excretion. That means, drug is absorbed first into the blood or lymphatic 
system, then is generally distributed to target organ(s) and produce desired effect(s); then 
goes to liver and metabolized there to inactive form(s) and finally, excreted through 
kidney. Exception is there, like some drugs after absorption into the system, first go to the 
liver and metabolized to more reactive form(s) and then go to the target organ(s) to 
produce the desired effect(s). However, all of theses four processes are very important 
consideration for product stewardship approaches because disturbance in any of these 
processes or incompleteness of any of theses processes results in excretion of active 
constituent(s) of drug formulation(s) into the environment.  
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If drugs are not completely absorbed into the system then non-absorbed portion 
excretes as such from the body; if the absorbed portion is not completely metabolized 
inside the body then the non-metabolized portion of the active constituents excrete as 
such into the environment; some time metabolized portions that excrete through kidney is 
more toxic in nature that the parent compounds. If drugs are not distributed properly into 
the system then it results in incomplete metabolism and excretion of active constituents 
from the body. Therefore, pharmaceutical industries are working on drug formulations 
for alteration or modification of formulations and/or modification of chemical structure 
of active constituents of drug, to increase drug absorption, to increase drug metabolism, 
to increase drug distribution and their target is to achieve 100% in all of drug absorption, 
distribution, metabolism processes to ensure that drug constituents are being excreted into 
the environment in least possible amount in their biologically most inactive form(s).   
 
Digoxin is used in cardiac disease like cardiac arrhythmia, ischemic heart disease 
etc. When Digoxin is administered orally, ~70% is absorbed into the blood, of which 
25% bounds to plasma proteins and transported to and localized in heart, skeletal muscle, 
liver and kidney; a small fraction is metabolized in liver to inactive products and is 
primarily excreted unchanged by glomerular filtration in kidney, has a total body 
clearance of ~ 150mL/min and a plasma half life (t1/2) of ~ 40 hours. Therefore, each 
single tablet of digoxin contributes active constituent to the environment to some extent 
through human fecal excretion. Moreover, the total amount of digoxin in each tablet 
should be the sum of the amount required to achieve the minimum effective 
concentration (MEC) in blood and the amount that is excreted unchanged from the body. 
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Therefore, this incomplete absorption and/or incomplete distribution and/or metabolism 
of drug not only gives rise to PPCPs issue but also, causing destruction of natural 
resources (as the active constituent of digoxin tablet is digitalis glycoside which is 
extracted from digitalis plants) and at the same time, increases the drug price in the 
market. So, modification of digoxin tablet formulation or modification of digitalis 
glycoside structure could enhance lipoprotein solubility of the active constituent, thereby 
increases drug absorption; similarly, it could increase drug-protein binding and thereby, 
increases drug distribution and drug-receptor binding at the target site(s). Therefore, less 
amount of drug will be required to incorporate into the dosage form to get the same effect 
while excretion of active constituent into the environment will be less.  In this way, 
product stewardship could help to solve all of the above mentioned issues. Under certain 
condition or disease state like vomiting, there is incomplete absorption of drugs that 
results in discharge of active constituents into the environment. This is not controllable 
through product stewardship.   
 
Pharmacy take-back program 
Another major source of PPCPs in the environment is improper household disposal of 
expired or unwanted prescription or Over-The-Counter (OTC) drugs by flushing them 
down the toilet or drain. Although it is an improper method of disposal of drugs 
containing different bio-reactive constituents but, it has become a traditional method and 
is widely being used now-a-days.  
The best method of disposal of household expired or unwanted prescription or 
Over-The-Counter (OTC) drugs is to return these medications to nearby pharmacies, 
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through pharmacy take-back program, for destruction. As per Daughton (The Green 
Pharmacy, 2003) –  
It is designed to accept the free return of all prescription and OTC medications 
(and certain other medically oriented products); it does not, however, accept 
physician samples. 
 
Besides local pharmacies, now-a-days pharmaceutical industries also have been 
started to participate in this program to collect both pharmacies’ own in-stock expired 
drugs and that collected by these pharmacies from consumers through pharmacy take-
back program, and to destroy these drugs in a proper manner.     
 
Pharmaceuticals mail-back program 
This is similar to pharmacy take-back program with the exception that under this 
program, instead of returning back to pharmacies, consumers are able to free return of 
their expired or unwanted prescription or Over-The-Counter (OTC) drugs directly to the 
participating pharmaceutical industries by postal mail services.  
The drawback of this program is that the postage requirements for mailing back 







II. Case Studies 
The websites of the following pharmaceutical companies have been visited to identify 
their respective approaches toward PPCPs in the environment.    
1. 3M Pharmaceuticals  
2. Abbott Laboratories   
3. Albert David Ltd   
4. AstaZeneca International  
5. Bristol Mayer Squibb  
6. GlaxoSmithKline  
7. Patheon, Inc.   
8. Pfizer  
9. Sandoz  
10. Wyeth Pharmaceuticals 
  
The different approaches that the pharmaceutical industries are using to address the issues 
of PPCPs, have been given in the following table: 
Table 5 







End-of-Pipe Wastewater Treatment 10 100 
Product Stewardship 8 80 
Combination of both the above 8 80 
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The different technologies that the pharmaceutical industries are using have been given in 











pH adjustment or Neutralization 10 100 




With Nitrification 6 60 
Without Nitrification 3 30 
Cyanide 
Destruction 
Alkaline Chlorination 1 10 
Hydrogen Peroxide Oxidation 1 10 
Basic Hydrolysis 0 00 
Multi-Media Filtration 6 60 
Polishing Pond 1 10 
Steam Stripping With Rectification 0 00 Without Rectification 1 10 
Granular Activated Carbon Absorption  7 70 
Air Stripping  3 30 
Incineration 2 20 
Product 
Stewardship  
Formulation Modification 8 80 
Structural Modification 6 60 
Pharmacy Take-Back 2 20 
Pharmaceutical Mail-Back 1 10 
 
The total number in the first column is greater than 10 and the total of the percentage in 
the second column is greater than 100 because some of those industries use more than 
one treatment technologies. 
 
 All of the industries that use either fermentation or chemical synthesis or both are 
using at least Advanced Biological Treatment technologies; some of them are using a 
combination of Advanced Biological Treatment and Effluent Filtration or Advanced 
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Biological Treatment and Polishing Pond, while the rest is using a combination of 
Advanced Biological Treatment and Effluent Filtration and Polishing Pond. All other 
industries that use either biological/natural extraction or mixing-compounding-
formulating or both are using at least Advanced Biological Treatment technologies; some 
of them are using a combination of Advanced Biological Treatment and Effluent 
Filtration.  
 
Bristol-Myers Squibb (Sermoneta, Italy) is using a system comprised of an 
advanced biological reactor with nitrification/denitrification combined with advanced 
ozone oxidation as a part of their wastewater treatment approaches while Pfizer 
(Ringaskiddy, Ireland), the GlaxoSmithKline (Carrigaline, Ireland) and Abbott 
Pharmaceuticals (Puerto Rico) are using ZeeWeed membrane bioreactors for reliable and 
effective treatment of wastewater, avoiding some problems experienced with 
conventional settlement technology. Wyeth Pharmaceuticals (Newbridge, Scotland) is 
using a combination of membrane bioreactor and ozone treatment system to treat 
wastewater stream onsite. AstraZeneca also treats many of its wastewater streams using 
onsite biological treatment units. 3M Pharmaceuticals and Sandoz (New York) use 
filtration technology as a main part of their wastewater treatment while Patheon, Inc. 
(Whitby, Canada) use a combination of Steam Stripping and onsite biological treatment 
unit to treat their wastewater stream.  Albert David Ltd. use cyanide destruction and air 
stripping system in combination with onsite biological treatment system to treat 
wastewater treatment. Albert David Ltd. also uses onsite polishing pond to treat their 
wastewater streams.   
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Most of these 10 industries are also using product stewardship approaches. The 
specific product stewardship programs are formulation modification, structural alteration, 
pharmacy take-back program and pharmaceuticals mail-back program. Formulation 
modification is the most common program that industries are using to reduce 
environmental impacts of their products while some industries are concentrating on 
pharmacokinetic properties of drug molecules and are trying to reduce environmental 
impacts of their products through structural modification of the active ingredients. A very 
few of them have participated in pharmacy take-back program and one of them has 





III. Interviews:  
According to responses to the Detailed Questionnaire of the interviews:  
∗   All of the ten pharmaceutical manufacturing facilities reported using pH 
adjustment or neutralization treatment of their wastewater stream as a 
pretreatment, prior to other physical, chemical and biological wastewater 
treatment processes to improve their effectiveness. Advanced biological 
treatment process is highly pH sensitive and so, pH adjustment is necessary 
before advanced biological treatment of wastewater. Also pH plays an important 
role in solubility of many wastewater contaminants and pH adjustment helps to 
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remove these contaminants through precipitation.  However, this is a chemical 
addition process and different neutralizing chemicals are added during the 
process that increases total chemical load. CaO, Ca(OH)2, NaOH etc. are usually 
used to raise pH while HCL, SO2 gas, H2SO4 etc. are normally used to lower pH 
of the wastewater stream. Some facilities are using liquefied CO2 in place of 
H2SO4. NaOH is expensive and CaO is very cheap and easily available. 
Therefore, CaO is the most preferred agent for treating acidic wastewater 
stream.  Eight of the ten pharmaceutical manufacturing facilities  reported using 
flow equalization unit to consolidate smaller volumes of wastewater streams so 
that, for batch treatment systems, full batch volumes are available and at the 
same time, to eliminate or at least to minimize shock loadings throughout the 
downstream of wastewater treatment processes to prevent system overloading.  
 
∗   Nine of the ten pharmaceutical manufacturing facilities reported using advanced 
biological treatment unit to remove organic and inorganic contaminants of their 
wastewater stream. Activated sludge is the most preferred process as it produces 
a very clean effluent within a reasonable period of time and not affected by 
external temperature conditions. Although surface impoundment is the cheapest 
method and can tolerate a large amount of potentially toxic chemicals, it is not 
preferred due to large amount of expensive land space requirement. Sequential 
batch reactor (SBR) and Rotating biological contractor (RBC) are not preferred 
due to high installation and high operational costs. Now-a-days, many industries 
are preferring membrane bioreactor technology for reliable and effective 
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treatment of wastewater, avoiding some problems experienced with 
conventional activated sludge process. Bristol Mayer Squibb (Sermoneta) is 
using a system comprised of an advanced biological reactor with 
nitrification/denitrification combined with advanced ozone oxidation to reduce 
hard COD. The GlaxoSmithKline (Carrigaline) is using a system consists of an 
equalization tank, pretreatment screening, a combination bioreactor and 
filtration tank equipped with fine bubble diffused aeration for aerobic biological 
treatment and ZeeWeed UF membranes. As per Mr. Simon of GlaxoSmithKline 
– “We use MBR technology as it offers a proven alternative to conventional 
approaches to the treatment of PWW, which poses particular problems for 
conventional treatment technology due to variations in feed-water strength and 
potential shock loading, and high dissolved solids content leading to floc 
destabilization and subsequent biomass leakage, resulting in a deterioration in 
treated effluent quality. Moreover, this generates an effluent permeate of 
consistently high quality, superior in performance to CAS alternatives. This 
MBR technology has proved valuable in achieving reliable and cost-effective 
treatment for our global pharmaceutical industry.” Pfizer (Ringaskiddy) is using 
membrane bioreactor technology effectively overcomes the problems associated 
with poor settling of sludge in conventional activated sludge processes. Abbott 
Pharmaceuticals (Puerto Rico) is using membrane bioreactors as MBR process 
combines the unit operations of aeration, secondary clarification and filtration 
into a single process, producing a high quality effluent, simplifying operation 
and greatly reducing space requirements.  
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∗   Two of the ten pharmaceutical manufacturing facilities reported using cyanide 
destruction process to remove cyanide compounds or cyanide ions from their 
wastewater stream. Alkaline chlorination is the most preferred process as within 
an extended retention time and in presence of heat, it results in complete 
destruction of total cyanides of wastewater stream. Hydrogen peroxide method 
is not preferred as it requires high pH and reaction rate is slow, requires copper 
catalyst to accelerate the reaction rate and copper recovery increases operational 
cost.   
 
∗   Six of the ten pharmaceutical manufacturing facilities reported using multi-
media filtration system as it is able to filter wastewater stream with a very high 
amount of turbidity or suspended solids and a very high degree of clarity is 
achieved because pore size of the filtration bed decreases as the wastewater 
stream passes towards bottom of the bed. It is preferred over single media 
filtration system as it filters wastewater stream at a much higher flow rate and 
has a longer running time than a single media filtration unit. As per Mr. Bill N. 
of 3M Corporate Communication – “We use a number of different technologies 
depending on the facility.  The most common technology for treating waste 
water at 3M is a filter technology.”  
 
∗   One of the ten pharmaceutical manufacturing facilities  reported using polishing 
pond to remove suspended solids from their wastewater stream. Although the 
 58
operation is very simple but, polishing pond is not preferred due to large amount 
of expensive land space requirement.  
 
∗   One of the ten pharmaceutical manufacturing facilities have been reported using 
stream stripping process to remove volatile contaminant of their wastewater 
stream. This process is preferred over air stripping in that, unlike air stripping, 
resultant off-gas stream is usually condensed and the contained constituents is 
recovered or incinerated.  
 
∗   Seven of the ten pharmaceutical manufacturing facilities reported using granular 
activated carbon adsorption to remove dissolved or suspended organic and 
inorganic contaminant of their wastewater stream. It is a highly preferred 
process of wastewater treatment due to its low space requirements and low 
operational and maintenance cost requirements.  
 
∗   Two of the ten pharmaceutical manufacturing facilities have been reported using 
incineration process for complete destruction of all contaminants of wastewater 
stream and 3 of the 10 pharmaceutical manufacturing facilities have been 
reported using air stripping to remove volatile organic and inorganic 
contaminant of their wastewater stream. Although air stripping is a cost-
effective method but is not preferred as it discharges volatile contaminants into 
the surrounding atmosphere.  
 
 59
∗   Eight of the ten pharmaceutical manufacturing facilities have been reported 
being involved with different product stewardship programs. All of them, who 
have participated in product stewardship, are doing research on formulation 
modification or alteration in order to substitute eco-toxic ingredients like 
different additives in dosage forms i.e. binding agent, dissolution agent, 
disintegrating agent, preservatives, emulsifying agents etc. from their 
formulations with biologically inert substances or eliminate these at all. 6 out of 
these 8 industries are involved in research on structural modification of drug 
molecules in order to improve pharmacokinetic properties of those molecules, 
thereby ensuring more effectiveness of the drugs and less fecal excretion into the 
environment.  Two of these eight industries have participated in pharmacy take-
back program to assist pharmacies in proper disposal of the expired or partially 
used prescription and non-prescription drugs, collected from local residents. One 
of these industries has also started pharmaceutical mail-back program to collect 
expired or partially used prescription and non-prescription drugs directly from 
the customer and dispose the same in an environmentally friendly manner. As 
per Mr. Simon of GlaxoSmithKline “We have voluntarily started to collect 
unwanted medicines from customers through pharmacy take back program and 
pharmaceuticals mail back program to make sure that drugs are not being 
disposed in an improper manner by the customers. In near future, we have a plan 





From both the case studies and interview, it has been found that all 
pharmaceutical industries are involved in onsite wastewater treatment operation to some 
extent. They do pH adjustment and filtration at minimum. The wastewater treatment 
technologies vary from unit to unit according to the type of chemical used and the type of 
pharmaceutical manufacturing process in place. As the wastewater treatment technologies 
are chemical specific or process specific, therefore the question of determining the best 
treatment technology is not relevant here.  
 
All of the pharmaceutical industries, contacted for the purpose of this research, 
believe that product stewardship is the best approaches to address the issue of PPCPs on a 
long term basis. Product stewardship is not economically feasible in all the cases and 
end-of-pipe wastewater treatment is the best option there. However, two of these ten 
pharmaceutical industries who are not currently involved in any of the product 
stewardship approaches, have a plan to become actively involved  in near future, in 
addition to their end-of-pipe wastewater treatment activities because all the 
pharmaceutical industries believe that neither end-of-pipe wastewater treatment activities 
nor the product stewardship approaches could alone address the issues of PPCPs in the 







Proactive approach, if economically feasible, is always preferred over reactive approach 
as it provides a long term solution to the problem. Moreover, proactive approach gives 
more economic benefit on a long-term run than that of reactive approach. The same 
concept is also true in case of addressing the issues of PPCPs in the environment. In this 
case, proactive approach like different product stewardship methods is considered better 
than reactive approach like different wastewater treatment methods. However, none of 
these two approaches could alone address the issues of PPCPs in the environment; rather 
a combination of different product stewardship approaches with some kind of wastewater 
treatment methods could address the issues more effectively.   
 
As the major sources of PPCPs in the environment are human excreta and 
improper disposal of unwanted medicine, different product stewardship approaches have 
been proved very effective in addressing the issues. Besides formulation modification and 
structural modification of drug components, pharmacy take-back program could also play 
a major role in addressing the issues but, lack of incentive resists people from 
participating into this program. In fact, expired or unwanted medicines in acceptable 
condition (i.e. such a physical condition of the formulation that does not show any sign of 
contamination or deterioration or any other kind of changes) could be collected either 
through pharmacy take-back program or through pharmaceuticals mail-back program 
from customers for the purpose of recovering active ingredients of drug formulation, 
thereby saving the cost of expensive active ingredients for the next batch(s) of medicine 
which, in turn, could allow the Pharmaceutical companies to provide some incentive, in 
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the form of price discount, to their customers to encourage them to participate more and 
more in Product Stewardship programs. This concept has been praised by Mr. Simon of 
GlaxoSmithKline and he also believes that this concept could be proved beneficial to 
Pharmaceutical Companies.  
 
For the purpose of this paper, a few of the renowned pharmacies like CVS 
pharmacy, Rite Aid pharmacy, Duane Reade pharmacy and Sunnyside Pharmacy have 
been contacted and as per their statistics, only 2% of their total customers (assuming that 
50% of total customers have unwanted medicines) have participated in pharmacy take-
back program. The pharmacy personnel believe that this percentage could be increased 
by providing some kind of incentives to the participants and particularly, the Sunnyside 
pharmacy likes the concept mentioned in the above paragraph because that concept could 
help pharmacies to provide 1-2% discount to the participants on the price of their next 
purchase of the similar category of drugs which could act as an incentive and would 
encourage people to participate more and more into the product stewardship program. 
Therefore, how this concept will work? People return unwanted i.e. expired medicines to 
the pharmacies. Expired medicine does not mean that it has reduced efficacy or no 
efficacy, rather in most of the cases, it has full efficacy as unexpired medicine. In fact, 
pharmaceutical manufacturers set this expiry date as 1/10th of the actual shelf life of the 
formulation to avoid any deformity in the formulation like color change, phase separation 
etc. Therefore, pharmaceutical manufacturer could collect these expired medicines in 
acceptable condition from consumers through pharmacies and could extract the active 
ingredients of those formulations and also could use these active ingredients in the 
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manufacture of fresh batches of medicines. In this way, pharmaceutical manufacturer 
could save the cost of active ingredients of formulations (if the extraction cost is less than 
the cost of procuring active ingredients from other sources) which could, in turn, allow 
them to provide discount to the participating customers on the price of their next purchase 
of the similar category of drugs. As for example, if a customer returns an antimicrobial 
drug of quinolones group to a participating pharmacy, the pharmacy will issue a discount 
coupon to that customer and upon producing this coupon to a participating pharmacy, the 
customer will get a discount on the price of their next purchase of any quinolones group 
of antimicrobial preparation. This discount money will inspire more people to participate 
in the pharmacy take-back program. In this way, pharmaceutical industries could also 
actively participate in the pharmacy take-back program and both, pharmaceutical 
industries and their ultimate consumer could be benefited and at the same time, problem 
of improper household disposal of unwanted medicine could be solved. In the similar 
way, pharmaceutical mail-back program could also be very effective in addressing the 
issues of PPCPs in the environment.  
 
Regarding participation issue related to pharmacies, there is no legislation till to 
date for pharmacies to participate in pharmacy take back program; rather the approach is 
totally voluntary, but it can be hoped, this would become legislation in the near future.  In 
addition to all of the above mentioned approaches, educating people about the issues of 
PPCPs is another very useful product stewardship approach that some pharmaceutical 
companies and pharmacies have voluntarily started e.g. Sunnyside pharmacy distributes a 
quarterly environmental awareness leaflets within the local community for fostering the 
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environmental awareness among the general public. If other pharmaceutical companies 
and pharmacies come forward to take such a voluntary initiative, then dealing with the 
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• What are the most recent approaches from company’s perspective to address this 
issue? 
• Why they have chosen any particular approach? 
• Why they are not using any other approaches? 
• What onsite wastewater treatment technologies they are using? What is their 
limitation(s)?   
• What they think about the best way to address the issue of PPCPs? 
• What they are thinking to do in near future regarding the issue of PPCPs? 
•  Are they doing so actually to protect our environment, or just due to some 












Website of Pharmaceutical Industries Visited for Case Study Purpose:  
3M Pharmaceuticals – www.3M.com  
Abbott Laboratories – www.abbott.com  
Albert David Ltd – www.albertdavidindia.com  
AstaZeneca International – www.astazeneca.com  
Bristol Mayer Squibb – www.bms.com  
GlaxoSmithKline – www.gsk.com  
Patheon, Inc. – www.patheon.com  
Pfizer – www.pfizer.com  
Sandoz – www.sandoz.com  
Wyeth Pharmaceuticals – www.wyeth.com  
  
